Shares of CSL (ASX:CSL) fell 1% in recent Tuesday trade after the Australian National Audit Office said in a Monday statement that the procurement of onshore manufacturing capability for antivenoms and vaccines by the company's unit Seqirus "did not maximize value for money for the Australian taxpayer in the long term."

The office said the procurements needed earlier planning and clearer value-for-money conclusions.

CSL did not immediately respond to MT Newswires' email request for comment.